Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone Benzoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 18/20 | 0.77 |
| ▸ | PGR | P06401 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | MMP1 | P03956 | 17/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone Benzoate SCHEMBL49469 | 1.00 | NR3C1 (0.77) | NR3C1PGRMEN1USP2CYP3A4 | |
| Betamethasone Benzoate SCHEMBL11878006 | 1.00 | NR3C1 (0.77) | NR3C1PGRMEN1USP2CYP3A4 | |
| Betamethasone Benzoate SCHEMBL11877997 | 1.00 | NR3C1 (0.77) | NR3C1PGRMEN1USP2CYP3A4 | |
| Betamethasone Benzoate SCHEMBL21682645 | 0.98 | NR3C1 (0.77) | NR3C1PGRMEN1USP2CYP3A4 | |
| Betamethasone Benzoate SCHEMBL6898101 | 0.94 | NR3C1 (0.88) | NR3C1PGRMEN1USP2CYP3A4 | |
| SCHEMBL11585136 | 0.94 | NR3C1 (0.67) | NR3C1PGRMEN1USP2CYP3A4 | |
| SCHEMBL11582817 | 0.93 | NR3C1 (0.80) | NR3C1PGRMEN1USP2CYP3A4 | |
| SCHEMBL11582821 | 0.93 | NR3C1 (0.80) | NR3C1PGRMEN1USP2CYP3A4 | |
| SCHEMBL11849050 | 0.93 | NR3C1 (0.80) | NR3C1PGRMEN1USP2CYP3A4 | |
| Betamethasone Dipropionate SCHEMBL5489443 | 0.93 | NR3C1 (0.83) | NR3C1PGRMEN1USP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10080785-B2 | Albumin fusion proteins | NOVOZYMES BIOPHARMA DK A/S (DK) | 2018-09-25 | — | — | US | disclosed |
| US-7785599-B2 | Using interferon alpha chimera to treat and prevent cell proliferative and viral diseases | HUMAN GENOME SCIENCES, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090285816-A9 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090105140-A1 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20080269127-A1 | Protein C; kits; pharmacokinetics | HUMAN GENOME SCIENCES, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269128-A1 | Apolipoproteins; kits; pharmacokinetics | HUMAN GENOME SCIENCES, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267962-A1 | Immunoglobulin fusion for treatment and prevention of cell proliferative and blood disorders | HUMAN GENOME SCIENCES, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269126-A1 | Factor X polypeptide fusion for treatment and prevention of cell proliferative, inflammatory, respiratory system and blood disorders; prolonging half-lives of serum polypeptides | HUMAN GENOME SCIENCES, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269125-A1 | Factor IX polypeptide fusion for treatment and prevention of cell proliferative, inflammatory, respiratory system and blood disorders; enhancing half-live of serum polypeptides | HUMAN GENOME SCIENCES, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080261877-A1 | Antihemophilic factor; kits; pharmacokinetics | HUMAN GENOME SCIENCES, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080131399-A1 | Using interferon alpha chimera to treat and prevent cell proliferative and viral diseases | HUMAN GENOME SCIENCES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 223/4885MEN1 2331/4885 |
| US-20080267962-A1 | Immunoglobulin fusion for treatment and prevention of cell proliferative and blood disorders | ALB, HDGF, HAVCR2 | NR3C1 2275/4885PGR 2556/4885MEN1 3108/4885 |
| US-20080269126-A1 | Factor X polypeptide fusion for treatment and prevention of cell proliferative, inflammatory, respiratory system and blood disorders; prolonging half-lives of serum polypeptides | F13B, F11, PGF | NR3C1 1719/4885PGR 2011/4885MEN1 3413/4885 |
| US-20090285816-A9 | Albumin Fusion Proteins | ALB, FABP1, TTR | NR3C1 3129/4885PGR 3615/4885MEN1 4035/4885 |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | NR3C1 1628/4885PGR 3140/4885MEN1 1417/4885 |
| US-20090105140-A1 | Albumin Fusion Proteins | ALB, FABP1, HDGF | NR3C1 3057/4885PGR 3639/4885MEN1 4180/4885 |
| US-20080131399-A1 | Using interferon alpha chimera to treat and prevent cell proliferative and viral diseases | HDGF, IRF3, ALB | NR3C1 2604/4885PGR 3433/4885MEN1 3555/4885 |
| US-20080269127-A1 | Protein C; kits; pharmacokinetics | ALB, FABP1, FABP3 | NR3C1 3101/4885PGR 2961/4885MEN1 3531/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR3C1 1628/4885PGR 3140/4885MEN1 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.